FDA Approves Mirum's Atebrioz (Zilurgisertib) as Third FOP Treatment, Intensifying Regeneron Rivalry
- The FDA approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib), an oral ALK2 inhibitor licensed from Incyte, for patients 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone disorder.
- It's the third approved FOP therapy, after Sohonos (palovarotene) and Regeneron's Pasatru (garetosmab), sharpening rivalry between Mirum and Regeneron.
- In its pivotal trial, Atebrioz notably reduced new heterotopic ossification (abnormal bone growth) versus placebo.
💡 Points
Three mechanisms chasing one ultra-rare population signals a share fight, not market expansion — FOP's patient pool won't stretch to reward a late third entrant on volume alone. Oral dosing is Mirum's real differentiator against Regeneron's IV antibody, and the Incyte in-license shows Mirum building a rare-bone-disease franchise by acquiring assets rather than discovering them.
Mirum bags FDA approval for ultra-rare bone lesion disorder, heating up rivalry with Regeneron ↗